HCW Biologics Inc (HCWB)
1.12
0.00 (0.00%)
USD |
NASDAQ |
Jun 14, 16:00
HCW Biologics Debt to Equity Ratio: 0.9606 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.9606 |
| December 31, 2023 | 0.4683 |
| September 30, 2023 | 0.2653 |
| June 30, 2023 | 0.2225 |
| March 31, 2023 | 0.1958 |
| December 31, 2022 | 0.1713 |
| September 30, 2022 | 0.1515 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.9606
Maximum
Mar 2024
0.1739
Average
0.0757
Median
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.5332 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 6.294 |
| Protalix BioTherapeutics Inc | 0.6856 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 30.43M |
| Total Liabilities (Quarterly) | 21.69M |
| Shareholders Equity (Quarterly) | 8.741M |
| Current Ratio | 0.4629 |
| Net Debt Paydown Yield | -0.60% |